Literature DB >> 26370105

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data from 10-Year Post-marketing Surveillance.

Francesca Renda1, Giovanni Landoni2,3, Renato Bertini Malgarini1, Alessandro Assisi1, Maria Luisa Azzolini4, Marta Mucchetti4, Giuseppe Pimpinella1, Luca Pani1.   

Abstract

INTRODUCTION: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare, severe and potentially fatal cutaneous adverse drug reaction (the mortality rate is up to 10 %) associated with numerous and apparently heterogeneous drugs. The aetiology is unknown.
OBJECTIVE: To report Italian cases of DRESS over a 10-year period.
METHODS: We searched the National Pharmacovigilance Network (NPN) for the term 'drug reaction with eosinophilia and systemic symptoms' from 1 January 2004 to 1 January 2014, to identify all reports of DRESS. Each case was checked to avoid duplication.
RESULTS: In the NPN, we identified 91 serious cases of DRESS: 68 were spontaneous, still-unpublished reports, while 23 additional cases were derived from screening of the scientific literature, performed by marketing authorization holders. Notably, the single common element linking all cases of DRESS was intake of a drug containing an aromatic ring.
CONCLUSION: Thanks to the largest national DRESS case series ever reported, we were able to hypothesize, for the first time, that there is an association between use of drugs containing an aromatic ring in their chemical structure and DRESS. This might aid understanding of the aetiology of DRESS and facilitate diagnosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26370105     DOI: 10.1007/s40264-015-0343-3

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.228


  28 in total

1.  [DRESS syndrome: 11 case reports and a literature review].

Authors:  Amel Chaabane; Karim Aouam; Nadia Ben Fredj; Naceur A Boughattas
Journal:  Therapie       Date:  2010-12-23       Impact factor: 2.070

2.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.

Authors:  Patricia T Illing; Julian P Vivian; Nadine L Dudek; Lyudmila Kostenko; Zhenjun Chen; Mandvi Bharadwaj; John J Miles; Lars Kjer-Nielsen; Stephanie Gras; Nicholas A Williamson; Scott R Burrows; Anthony W Purcell; Jamie Rossjohn; James McCluskey
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

3.  Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR).

Authors:  Yoko Kano; Mikiko Tohyama; Michiko Aihara; Setsuko Matsukura; Hideaki Watanabe; Hirohiko Sueki; Masafumi Iijima; Eishin Morita; Hiroyuki Niihara; Hideo Asada; Kenji Kabashima; Hiroaki Azukizawa; Hideo Hashizume; Keisuke Nagao; Hayato Takahashi; Riichiro Abe; Chie Sotozono; Michiko Kurosawa; Yumi Aoyama; Chia-Yu Chu; Wen-Hung Chung; Tetsuo Shiohara
Journal:  J Dermatol       Date:  2015-01-27       Impact factor: 4.005

4.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

5.  Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study.

Authors:  S H Kardaun; P Sekula; L Valeyrie-Allanore; Y Liss; C Y Chu; D Creamer; A Sidoroff; L Naldi; M Mockenhaupt; J C Roujeau
Journal:  Br J Dermatol       Date:  2013-11       Impact factor: 9.302

6.  Cutaneous adverse drug reactions in hospitalised patients.

Authors:  H Y Lee; L K Tay; T Thirumoorthy; S M Pang
Journal:  Singapore Med J       Date:  2010-10       Impact factor: 1.858

7.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

8.  Sulfasalazine-induced linear immunoglobulin A bullous dermatosis with DRESS.

Authors:  N Hernández; L Borrego; E Soler; J Hernández
Journal:  Actas Dermosifiliogr       Date:  2013-04-04

9.  Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan.

Authors:  Yi-Chun Chen; Chia-Ying Chang; Yung-Tsu Cho; Hsien-Ching Chiu; Chia-Yu Chu
Journal:  J Am Acad Dermatol       Date:  2012-09-06       Impact factor: 11.527

10.  Treatment of DIHS/DRESS syndrome with combined N-acetylcysteine, prednisone and valganciclovir--a hypothesis.

Authors:  Oswald Moling; Lukas Tappeiner; Andrea Piccin; Elisabetta Pagani; Patrizia Rossi; Giovanni Rimenti; Claudio Vedovelli; Peter Mian
Journal:  Med Sci Monit       Date:  2012-07
View more
  5 in total

1.  More than skin deep. Ten year follow-up of delayed cutaneous adverse drug reactions (CADR).

Authors:  Linda Velta Graudins; Jenny Ly; Jason Trubiano; Ar Kar Aung
Journal:  Br J Clin Pharmacol       Date:  2016-07-18       Impact factor: 4.335

Review 2.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist.

Authors:  Marwan H Adwan
Journal:  Curr Rheumatol Rep       Date:  2017-01       Impact factor: 4.686

3.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) with Teicoplanin: A Case Report.

Authors:  Sholeh Ebrahimpour; Mehdi Mohammadi; Kheirollah Gholami
Journal:  Drug Saf Case Rep       Date:  2017-12

4.  Drug Reaction with Eosinophilia and Systemic Symptoms: Retrospective Analysis of 104 Cases over One Decade.

Authors:  Li Wang; Xue-Ling Mei
Journal:  Chin Med J (Engl)       Date:  2017-04-20       Impact factor: 2.628

5.  DRESS syndrome in the setting of oxacillin therapy-a call for better patient preparedness: a case report.

Authors:  Hawa Ozien Abu; Sajjadh M J Ali; Anil Phuyal; Akil Sherif; Gregory T Williams; Iryna Chastain
Journal:  J Med Case Rep       Date:  2021-12-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.